APR 11, 2019

Axcella Presents Late-Breaker Data Demonstrating Lead AXA™ Candidate AXA1665 Impacted Markers Related to Liver Health

APR 2, 2019

Axcella Announces Patent Issuance for AXA™ Candidate AXA1125 Methods of Use

MAR 27, 2019

Axcella to Present Late-Breaker Data on lead AXA™ Candidate, AXA1665 at EASL, The International Liver Congress™

MAR 25, 2019

Axcella Appoints Shreeram Aradhye, M.B.B.S., M.D., as Executive Vice President, Chief Development Officer

Karen Lewis appointed Senior Vice President, Human Resources

FEB 12, 2019

Axcella Announces Patent Issuance for AXA Candidate AXA1125

JAN 24, 2019

Axcella Presents Mechanistic Data Demonstrating that AXA1125 Modulated Liver Metabolic, Inflammatory and Fibrotic Pathways

JAN 3, 2019

Axcella to Present Update at the 37th Annual JP Morgan Healthcare Conference

DEC 21, 2018

Axcella to Present Data on AXA1125 at Integrated Pathways of Disease in NASH and NAFLD Keystone Symposium

NOV 12, 2018

Data from Axcella’s AXA1125 Program Supports New Approach Leveraging Endogenous Metabolic Modulators to Reprogram Cellular Physiology

OCT 22, 2018

Axcella Appoints Stephen Mitchener, PharmD, to Senior Vice President, Chief Business Officer

OCT 22, 2018

Axcella to Present New Data at the Annual 2018 AASLD Liver Meeting

JUNE 27, 2018

Axcella Welcomes William D. Baird, and Cristina M. Rondinone, Ph.D., to Board of Directors

Axcella strengthens legal team with appointments of Paul F. Fehlner, J.D., Ph.D., as Senior Vice President, Chief Intellectual Property Officer and Heidy Abreu King-Jones, J.D., LL.M., as Vice President, Legal and Corporate Secretary

MAY 31, 2018

Axcella Appoints Bill Hinshaw as President and Chief Executive Officer



To be announced.